<html xmlns:fo="http://www.w3.org/1999/XSL/Format">

<!-- Mirrored from www.zambiahivguide.org/drugs/antiretrovirals/full_efavirenz.html by HTTrack Website Copier/3.x [XR&CO'2007], Thu, 19 Jun 2008 21:22:26 GMT -->
<head>
<META http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
<title>Johns Hopkins POC-IT: Point of Care Information Technology</title>
<meta content="text/html; charset=iso-8859-1" http-equiv="Content-Type">
<link href="../../images/styles.css" type="text/css" rel="stylesheet">
<script type="text/JavaScript" src="../../images/functions.js" language="JavaScript"></script>
</head>
<body>
<table cellspacing="0" cellpadding="0" border="0">
<tr>
<td>Johns Hopkins POC-IT: Point of Care Information Technology</td><td >
<table cellspacing="0" cellpadding="0" border="0">
<tr>
<td >
<table cellspacing="0" cellpadding="0" border="0">
<tr>
<td></td><td>
<table cellspacing="0" cellpadding="0" border="0">
<tr>
<td class="tdVAlignMiddle" align="center" >
                                                            &nbsp;</td>
</tr>
<tr></tr>
</table>
</td>
</tr>
</table>
</td>
</tr>
<tr>
<td  ><span class="mainNav">&nbsp;Print-Friendly Module</span></td>
</tr>
</table>
</td>
</tr>
</table>
<p></p>
<table cellspacing="0" cellpadding="0" border="0" >
<tr>
<td></td><td>
<table >
<tr>
<td><span class="primaryItemTitle"><font size="6">Efavirenz</font></span>
<br>
</td><td align="right" valign="top"><a href="javascript:window.print();"></a></td>
</tr>
<tr>
<td colspan="2">
<br>
        Author: <author maxOccurance="1" tag="author" use="required">Paul A. Pham, Pharm.D. and John G. Bartlett, M.D.</author>
<br>
<span class="display_date">03-24-2008</span>
<br>
<div style="background-color:#ccffcc;">
<a name=""></a>
<h2 class="grayLineHeaderBar"></h2>
<ul>
<li>
<B>Available formulation in Zambia: Capsule:</B> 50 mg; 100 mg; 200 mg; <B>Oral liquid: </B>150 mg/5 ml; <B>Tablet:</B> 600 mg. EFV&nbsp;600&nbsp;mg/<A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF</A>&nbsp;300&nbsp;mg/<A class="headLines" target="_new" href="emtricitabine63e5.html?contentInstanceId=432943">FTC</A>&nbsp;200&nbsp;mg combination tab. </li>
<li>
<A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF</A>/<A class="headLines" target="_new" href="emtricitabine63e5.html?contentInstanceId=432943">FTC</A> plus EFV is now the preferred first line regimen due to long-term efficacy and favorable side effect profile. </li>
<li>EFV is recommended NNRTI to be used with <A class="headLines" target="_new" href="../antimicrobial_agents/rifampicin532e.html?contentInstanceId=434653">rifampicin</A>. </li>
<li>EFV-based regimen not recommended for the treatment of HIV-2 infection. </li>
<li>To prevent NNRTI resistance with treatment discontinuation, discontinue EFV and continue NRTIs for an additional 10 days. </li>
<li>Contraindicated in 1st trimester of pregnancy. Birth defects occurred in 5 of 188 live births with 1st trimester exposure and in 0 of 13 live births with 2nd or 3rd trimester exposure. </li>
</ul>Zambia Information Author: Paul A. Pham, Pharm. D. <br>
<br>
</div>
<a name="INDICATIONS"></a>
<h2 class="grayLineHeaderBar">INDICATIONS</h2>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">FDA</span></td>
</tr>
</table>
<hr>
<ul>
<li>Treatment of HIV infection in combination with other antiretrovirals.</li>
</ul>
<a name="FORMS"></a>
<h2 class="grayLineHeaderBar">FORMS</h2>
<TABLE  class="blueOutline" cellspacing="0" cellpadding="2" border="0">
<TR class="blueBarBG">
<TD><B>brand name</B></TD><TD><B>preparation</B></TD><TD><B>manufacturer</B></TD><TD><B>route</B></TD><TD><B>form</B></TD><TD><B>dosage^</B></TD><TD><B>cost*</B></TD>
</TR>
        
<TR>
<TD valign="top"><I>Sustiva</I> (available in U.S., Canada, and some parts of Europe)</TD><TD valign="top">Efavirenz (EFV)</TD><TD valign="top">Bristol-Myers Squibb </TD><TD>oral</TD><TD>capsule</TD><TD>50 mg</TD><TD>$1.44</TD>
</TR>
<TR>
<TD valign="top">&nbsp;            
            </TD><TD valign="top">&nbsp;
            </TD><TD valign="top">&nbsp;                
            </TD><TD>oral</TD><TD>tablet</TD><TD>600 mg</TD><TD>$17.31</TD>
</TR>
<TR>
<TD valign="top">&nbsp;            
            </TD><TD valign="top">&nbsp;
            </TD><TD valign="top">&nbsp;                
            </TD><TD>oral</TD><TD>capsule</TD><TD>200 mg</TD><TD>$5.77</TD>
</TR>
<TR>
<TD valign="top">&nbsp;            
            </TD><TD valign="top">&nbsp;
            </TD><TD valign="top">&nbsp;                
            </TD><TD>oral</TD><TD>capsule</TD><TD>100 mg</TD><TD>$2.88</TD>
</TR>
        
<TR>
<TD valign="top"><I>Stocrin </I>(brand name available in South Africa, Southeast Asia, and other parts of the world)</TD><TD valign="top">Efavirenz (EFV)</TD><TD valign="top">Merck</TD><TD>oral</TD><TD>capsule</TD><TD>50 mg, 100 mg, 200 mg </TD><TD>variable</TD>
</TR>
<TR>
<TD valign="top">&nbsp;            
            </TD><TD valign="top">&nbsp;
            </TD><TD valign="top">&nbsp;                
            </TD><TD>oral </TD><TD>tablet</TD><TD>600 mg</TD><TD>variable</TD>
</TR>
<TR>
<TD valign="top">&nbsp;            
            </TD><TD valign="top">&nbsp;
            </TD><TD valign="top">&nbsp;                
            </TD><TD>oral </TD><TD>solution</TD><TD>30 mg/30 mL (180 mL bottle)</TD><TD>variable</TD>
</TR>
        
<TR>
<TD valign="top">Atripla (available in the U.S.)</TD><TD valign="top">EFV/<A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF</A>/<A class="headLines" target="_new" href="emtricitabine63e5.html?contentInstanceId=432943">FTC</A><SPAN class="TSTH"></SPAN></TD><TD valign="top">Bristol-Myers Squibb &amp; Gilead Sciences</TD><TD>oral</TD><TD>tablet</TD><TD>EFV&nbsp;600mg/<A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF</A>&nbsp;300mg/<A class="headLines" target="_new" href="emtricitabine63e5.html?contentInstanceId=432943">FTC</A>&nbsp;200mg </TD><TD>$47.95</TD>
</TR>
      
</TABLE>
<p>*Costs (rounded to the nearest dollar) are based on usual adult dosing per day, 
                are representative of "Average Wholesale Price" (AWP), and are current within the prior three months.</p>
<p>^Dosage is indicated in mg unless otherwise noted.</p>
<a name="USUAL ADULT DOSING"></a>
<h2 class="grayLineHeaderBar">USUAL ADULT DOSING</h2>Pill burden: 1 tab per day<br>
<br>
<ul>
<li>EFV 600 mg PO qd. Evening dosing on an empty stomach recommended initially to decrease side effects. </li>
<li>Can be administered as a co-formulated product with <A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF</A>/<A class="headLines" target="_new" href="emtricitabine63e5.html?contentInstanceId=432943">FTC</A> (<I>Atripla</I>) 1 tab PO&nbsp;qd.</li>
<li>Administration with food, especially with high fat meal, may increase CNS side effects: EFV peak levels increased by 40% (caps) and 80% (tabs). </li>
<li>For GI intolerance, consider taking with food after resolution of CNS side effects. </li>
<li>Morning CNS side effects may be decreased if taken several hrs before bedtime. Some pts can tolerate morning dosing after resolution of initial CNS side effects. </li>
<li>With <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV/r</A>: Consider <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV/r</A> 600/150 mg (3 tabs) bid + EFV 600 mg qhs, especially for PI-experienced pts. In PI-naive pts, standard dose of 400/100 (2 tabs) bid may be adequate.</li>
<li>With <A class="headLines" target="_new" href="fosamprenavir551f.html?contentInstanceId=441415">FPV</A>: <A class="headLines" target="_new" href="fosamprenavir551f.html?contentInstanceId=441415">FPV</A> 700 mg bid + <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> 100 mg bid OR <A class="headLines" target="_new" href="fosamprenavir551f.html?contentInstanceId=441415">FPV</A> 1400 mg + <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> 300 mg qd plus EFV 600 mg qhs.</li>
<li>With <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A>: <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A> 300 mg qd + <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> 100 mg qd + EFV 600 mg qhs. Consider TDM.</li>
<li>With&nbsp;<A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A>: <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A> 800 mg bid + <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> 200 mg bid + EFV 600 mg qhs.</li>
<li>With <A class="headLines" target="_new" href="saquinavir964d.html?contentInstanceId=432951">SQV</A>: <A class="headLines" target="_new" href="saquinavir964d.html?contentInstanceId=432951">SQV</A> 1000 mg bid + <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> 100 mg bid with EFV 600 mg qhs.</li>
<li>With <A class="headLines" target="_new" href="nelfinaviraafb.html?contentInstanceId=432948">NFV</A>: <A class="headLines" target="_new" href="nelfinaviraafb.html?contentInstanceId=432948">NFV</A> 1250 mg bid + EFV 600 mg qhs.</li>
<li>With <A class="headLines" target="_new" href="darunavir4a48.html?contentInstanceId=443123">DRV</A>:: Dose not established. Consider DRV/r 600/100 mg bid + EFV 600 mg qhs.</li>
<li>With <A class="headLines" target="_new" href="tipranavir9ea2.html?contentInstanceId=443122">TPV</A>: TPV/r 500/200 mg bid + EFV 600 mg qhs. </li>
<li>With raltegravir (MK-0518): dose not established.&nbsp;</li>
<li>With maraviroc: MVC 600 mg BID + EFV 600 mg qhs. Note: if PIs (i.e <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV/r</A> or SQV/r) contained in regimen, standard dose MVC recommended.</li>
</ul>
<a name="RENAL DOSING"></a>
<h2 class="grayLineHeaderBar">RENAL DOSING</h2>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING FOR GLOMERULAR FILTRATION OF 50-80</span></td>
</tr>
</table>
<hr>600 mg qhs <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING FOR GLOMERULAR FILTRATION OF 10-50</span></td>
</tr>
</table>
<hr>600 mg qhs. Avoid EFV/<A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF</A>/<A class="headLines" target="_new" href="emtricitabine63e5.html?contentInstanceId=432943">FTC</A> co-formulation tab with GFR &lt;50 ml/min. <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING FOR GLOMERULAR FILTRATION OF &lt;10 ML/MIN</span></td>
</tr>
</table>
<hr>600 mg qhs. Avoid EFV/<A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF</A>/<A class="headLines" target="_new" href="emtricitabine63e5.html?contentInstanceId=432943">FTC</A> co-formulation tab with GFR &lt;50 ml/min. <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING IN HEMODIALYSIS</span></td>
</tr>
</table>
<hr>600 mg qhs (EFV PK not affected by HD). Avoid EFV/<A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF</A>/<A class="headLines" target="_new" href="emtricitabine63e5.html?contentInstanceId=432943">FTC</A> co-formulation tab with GFR &lt;50 ml/min. <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING IN PERITONEAL DIALYSIS</span></td>
</tr>
</table>
<hr>600 mg qhs (limited data). Avoid EFV/<A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF</A>/<A class="headLines" target="_new" href="emtricitabine63e5.html?contentInstanceId=432943">FTC</A> co-formulation tab with GFR &lt;50 ml/min. <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING IN HEMOFILTRATION</span></td>
</tr>
</table>
<hr>No data. Consider 600 mg qhs. <br>
<br>
<a name="ADVERSE DRUG REACTIONS"></a>
<h2 class="grayLineHeaderBar">ADVERSE DRUG REACTIONS</h2>Generally well tolerated after resolution of CNS side effects (2-4 wks).<br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">COMMON</span></td>
</tr>
</table>
<hr>
<ul>
<li>CNS effects: vivid dreams including nightmares, nocturnal dizziness, morning confusion; depersonalization; usually seen during1st 2-4 wks with gradual resolution in most pts.</li>
<li>Pts experiencing early CNS toxicity should avoid tasks that require concentration, such as driving, especially in the morning. </li>
<li>Pts should be advised of additive effects of alcohol and other psychoactive agents when coadministered with EFV. </li>
<li>Morbilliform rash in up to 26% of pts&nbsp;requiring discontinuation in 1.7% (med. onset&nbsp;11 days, duration 16 days); incidence and severity lower than <A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">NVP</A>. Generally resolves with continued use of EFV.</li>
<li>False-positive urine toxicology screening test for cannabinoids (w/CEDIA DAU Multilevel THC assay only); confirmatory tests negative.</li>
</ul>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">OCCASIONAL</span></td>
</tr>
</table>
<hr>
<ul>
<li>Elevated triglycerides and cholesterol (incidence higher than for <A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">NVP</A>).</li>
<li>Elevated transaminases (2-8%; incidence and severity lower compared than for <A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">NVP</A>).</li>
</ul>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">RARE</span></td>
</tr>
</table>
<hr>
<ul>
<li>Erythema multiforme and Stevens-Johnson syndrome (0.1%).</li>
<li>Gynecomastia. </li>
<li>Severe psychiatric disorders, primarily <A class="headLines" target="_new" href="../../diagnosis/organ_system/depression91f0.html?contentInstanceId=432752">depression</A> reported in 2.4%.</li>
</ul>
<a name="DRUG INTERACTIONS"></a>
<h2 class="grayLineHeaderBar">DRUG INTERACTIONS</h2>Substrate of CYP3A4 and CYP2B6; inducer of CYP3A4 and CYP2B6; weak inhibitor of CYP3A4, 2B6, 2C9, and 2C19. Inducers of CYP3A4 and CYP2B6 may decrease EFV serum levels. EFV generally decreases serum levels of CYP3A4 and CYP2B6 substrates. <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">Drug-to-Drug Interactions</span></td>
</tr>
</table>
<hr>
<a name="Drug-to-Drug Interaction"></a>
<h2 class="grayLineHeaderBar">Drug-to-Drug Interaction</h2>
<TABLE class="blueOutline" CELLPADDING="2" CELLSPACING="0"  BORDER="0">
<tr class="blueBarBG">
<td>Drug</td><td>Effect of Interaction</td><td>Recommendations/Comments</td>
</tr>
<TR>
<TD valign="top"><B>&nbsp;<A class="headLines" target="_new" href="../antimicrobial_agents/amodiaquine305e.html?contentInstanceId=434591">Amodiaquine</A>&nbsp;</B></TD><TD valign="top"><A class="headLines" target="_new" href="../antimicrobial_agents/amodiaquine305e.html?contentInstanceId=434591">Amodiaquine</A> AUC increased with co-administration. </TD><TD valign="top">Co-administration of EFV with artesunate plus <A class="headLines" target="_new" href="../antimicrobial_agents/amodiaquine305e.html?contentInstanceId=434591">amodiaquine</A> may result in significant LFT elevations. With EFV co-administration, significant increase in <A class="headLines" target="_new" href="../antimicrobial_agents/amodiaquine305e.html?contentInstanceId=434591">amodiaquine</A> AUC (114% and 302%) reported in 2 pts. </TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A>
          </B></TD><TD valign="top"><A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A> AUC: decreased 74%; Cmin: decreased 93% (without <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> co-administration) <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A> AUC: increased 241%; Cmin: increased 671% (with <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> co-administration).</TD><TD valign="top">Recommended dosing: <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A> 300 mg + <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> 100 mg qd + EFV 600 mg qhs&nbsp;(consider <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A>&nbsp;TDM esp. in PI-experienced patients). Unboosted <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A> (without <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A>) not recommended with EFV.</TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="../antimicrobial_agents/azithromycin9ba3.html?contentInstanceId=441410">Azithromycin</A>
          </B></TD><TD valign="top"><A class="headLines" target="_new" href="../antimicrobial_agents/azithromycin9ba3.html?contentInstanceId=441410">Azithromycin</A> AUC unchanged</TD><TD valign="top">No significant interaction. Use standard dose.</TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="../antimicrobial_agents/clarithromycin2448.html?contentInstanceId=434158">Clarithromycin</A>
          </B></TD><TD valign="top"><A class="headLines" target="_new" href="../antimicrobial_agents/clarithromycin2448.html?contentInstanceId=434158">Clarithromycin</A> AUC: decreased 39%; 14-hydroxyclarithromycin AUC: increased 34%.</TD><TD valign="top">Clinical significance unknown. High incidence of rash seen in healthy volunteer receiving this combination. Consider alternative macrolide (<A class="headLines" target="_new" href="../antimicrobial_agents/azithromycin9ba3.html?contentInstanceId=441410">azithromycin</A>).</TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="../antimicrobial_agents/fluconazoled462.html?contentInstanceId=434183">Fluconazole</A>
          </B></TD><TD valign="top"><A class="headLines" target="_new" href="../antimicrobial_agents/fluconazoled462.html?contentInstanceId=434183">Fluconazole</A> AUC increased 16%.</TD><TD valign="top">No significant interaction. Use standard dose.</TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="fosamprenavir551f.html?contentInstanceId=441415">FPV</A>
          </B></TD><TD valign="top">APV Cmin decreased by 36% (dose used <A class="headLines" target="_new" href="fosamprenavir551f.html?contentInstanceId=441415">FPV</A> 1400 mg qd plus <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> 200 mg qd). APV Cmin decreased by 17% (dose used <A class="headLines" target="_new" href="fosamprenavir551f.html?contentInstanceId=441415">FPV</A> 700 mg bid + <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A>100 mg bid).</TD><TD valign="top">Recommended dosing: <A class="headLines" target="_new" href="fosamprenavir551f.html?contentInstanceId=441415">FPV</A> 1400 mg + <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> 300 mg qd(in PI-naive pts only) or <A class="headLines" target="_new" href="fosamprenavir551f.html?contentInstanceId=441415">FPV</A> 700 mg bid + <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> 100 mg bid + EFV 600 mg qhs.</TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A>
          </B></TD><TD valign="top"><A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A> AUC: decreased 19%; Cmin: decreased 48%.</TD><TD valign="top">Clinically significant: Recommended dose: <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A> 1000 mg q8h + EFV 600 mg qhs OR <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A> 800 mg bid + <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> 200 mg bid + EFV 600 mg qhs.</TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV/r</A>
          </B></TD><TD valign="top">LPV AUC decreased (non-significant); Cmin decreased 39%.</TD><TD valign="top">Clinically significant: Consider <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV/r</A>&nbsp;600/150 mg (3&nbsp;tabs) bid + EFV 600 mg qhs, especially in PI-experienced pts. Standard dose of 400/100 mg bid may be adequate in PI-naive pts. </TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="nelfinaviraafb.html?contentInstanceId=432948">NFV</A>
          </B></TD><TD valign="top"><A class="headLines" target="_new" href="nelfinaviraafb.html?contentInstanceId=432948">NFV</A> AUC: increased 20%. M8 AUC: decreased 37%.</TD><TD valign="top">No significant interaction. Use standard dose: <A class="headLines" target="_new" href="nelfinaviraafb.html?contentInstanceId=432948">NFV</A> 1250 mg bid + EFV 600 mg qhs.</TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">NVP</A>
          </B></TD><TD valign="top">EFV AUC: decreased 22%; Cmin: decreased 36%.</TD><TD valign="top">Co-administration not recommended due to overlapping resistance profile. With co-administration consider increasing EFV to 800 mg qd.</TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="../antimicrobial_agents/rifampicin532e.html?contentInstanceId=434653">Rifampin</A>
          </B></TD><TD valign="top">EFV AUC: decreased 26%; no change in <A class="headLines" target="_new" href="../antimicrobial_agents/rifampicin532e.html?contentInstanceId=434653">rifampin</A> AUC.</TD><TD valign="top">Recommended dosing: EFV 800 mg/d with <A class="headLines" target="_new" href="../antimicrobial_agents/rifampicin532e.html?contentInstanceId=434653">rifampin</A> 600 mg qd (monitor for EFV CNS side effects). May decrease to EFV 600 mg/d if 800 mg dose not easily tolerated.</TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A>
          </B></TD><TD valign="top"><A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> AUC: increased 18% EFV AUC: increased 21%.</TD><TD valign="top">No significant interaction. Use standard dose of <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> and EFV.</TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="saquinavir964d.html?contentInstanceId=432951">SQV</A>
          </B></TD><TD valign="top">SQV/r AUC: decreased 62% (with unboosted <A class="headLines" target="_new" href="saquinavir964d.html?contentInstanceId=432951">SQV</A>) <A class="headLines" target="_new" href="saquinavir964d.html?contentInstanceId=432951">SQV</A> Cmin: decreased 10% (w/ boosted <A class="headLines" target="_new" href="saquinavir964d.html?contentInstanceId=432951">SQV</A> 400 mg/<A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> 400 mg); <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> Cmin: no significant change EFV: no significant change.</TD><TD valign="top">Do not coadminister unboosted <A class="headLines" target="_new" href="saquinavir964d.html?contentInstanceId=432951">SQV</A> with EFV. Recommended dose: <A class="headLines" target="_new" href="saquinavir964d.html?contentInstanceId=432951">SQV</A> 1000 mg + <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> 100 mg bid + EFV 600 mg qhs.</TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="darunavir4a48.html?contentInstanceId=443123">Darunavir</A>
          </B></TD><TD valign="top">DRV Cmin decreased by 31%. EFV AUC and Cmin increased 21% and 17%, respectively (studied with DRV/r 300/100 mg bid). </TD><TD valign="top">Dose not established. Consider DRV 600/100 mg bid with EFV 600 mg qhs. </TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="tipranavir9ea2.html?contentInstanceId=443122">Tipranavir</A>
          </B></TD><TD valign="top">No significant change in TPV and EFV PK parameters with higher TPV/r dose (750mg/200mg BID) </TD><TD valign="top">Consider TPV/r 500/200 mg bid + EFV 600mg QD. </TD>
</TR>
<TR>
<TD valign="top"><B>Artemether (artemisinin)</B></TD><TD valign="top">May decrease serum level of artemether</TD><TD valign="top">Close monitoring of artemether therapeutic efficacy (i.e parasite count on blood smear and clinical signs and symptoms of clinical improvement). Co-administration of EFV with artesunate plus <A class="headLines" target="_new" href="../antimicrobial_agents/amodiaquine305e.html?contentInstanceId=434591">amodiaquine</A> may result in significant LFT elevations. </TD>
</TR>
<TR>
<TD valign="top"><B>Astemizole</B></TD><TD valign="top">May significantly increase astemizole serum level</TD><TD valign="top">Contraindicated due to the potential for cardiac arrhythmias. Recommended alternative antihistamine: loratadine, fexofenadine, desloratidine, or cetirizine.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Atorvastatin
          </B></TD><TD valign="top">Atorvastatin: AUC decreased by 43%.</TD><TD valign="top">May require atorvastatin dose increase with close monitoring of LFTs and CPK.</TD>
</TR>
<TR>
<TD valign="top"><B>Azathioprine</B></TD><TD valign="top">Interaction unlikely</TD><TD valign="top">Applies to all PIs and NNRTIs: Use standard dose.</TD>
</TR>
<TR>
<TD valign="top"><B>Buprenorphine </B></TD><TD valign="top">Buprenorphine AUC and Cmin decreased by 50%. EFV not affected. </TD><TD valign="top">No withdrawal symptoms noted when buprenorphine Cmin decreased from 0.85 ng/ml to 0.42 ng/ml. It should be noted that withdrawal symptoms may not be seen until a decrease to 0.23 ng/ml. Use standard dose buprenorphine with titration to therapeutic effect. </TD>
</TR>
<TR>
<TD valign="top"><B>
            Bupropion
          </B></TD><TD valign="top">May increase bupropion serum level slightly</TD><TD valign="top">Not likely to be clinically significant. Start with lowest possible dose of bupropion with co-administration. In a small case series no seizures reported with co-administration.</TD>
</TR>
<TR>
<TD valign="top"><B>Carbamazepine</B></TD><TD valign="top">Efavirenz AUC decreased by 34% and carbamazepine AUC decreased by 27%. </TD><TD valign="top">Avoid co-administration. Consider alternative anticonvulsant (e.g., valproic acid, lamotrigine, levetiracetam, or topiramate). With coadministration, monitor carbamazepine levels and consider efavirenz TDM.</TD>
</TR>
<TR>
<TD valign="top"><B>Caspofungin</B></TD><TD valign="top">May decrease caspofungin serum level.</TD><TD valign="top">Monitor for caspofungin therapeutic failure, may need to increase dose to 70 mg/d.</TD>
</TR>
<TR>
<TD valign="top"><B>Cetirizine</B></TD><TD valign="top">EFV: no significant change cetirizine: no change</TD><TD valign="top">No significant interaction. Use standard dose of both drugs.</TD>
</TR>
<TR>
<TD valign="top"><B>Cisapride</B></TD><TD valign="top">May increase cisapride serum level.</TD><TD valign="top">Contraindicated due to potential for cardiac arrhythmias. Recommended alternative: metoclopramide.</TD>
</TR>
<TR>
<TD valign="top"><B>Cocaine</B></TD><TD valign="top">May theoretically increase serum level of hepatotoxic metabolite.</TD><TD valign="top">Avoid illicit drugs for obvious reasons.</TD>
</TR>
<TR>
<TD valign="top"><B>Cyclophosphamide</B></TD><TD valign="top">May decrease serum level of cyclophosphamide.</TD><TD valign="top">No data. Monitor for chemotherapeutic response. Cyclophosphamide dose may need to be increased.</TD>
</TR>
<TR>
<TD valign="top"><B>Cyclosporine</B></TD><TD valign="top">May significantly decrease serum level of cyclosporine.</TD><TD valign="top">Monitor serum level of cyclosporine closely with co-administration. Cyclosporin dose may need to be increased.</TD>
</TR>
<TR>
<TD valign="top"><B>Diltiazem </B></TD><TD valign="top">Diltiazem AUC decreased by 69% with co-administration. EFV AUC increased by 11%. </TD><TD valign="top">Titrate diltiazem dose to effect. Higher diltiazem and other Ca channel blocker doses may be needed. </TD>
</TR>
<TR>
<TD valign="top"><B>Docetaxel</B></TD><TD valign="top">May decrease serum level of docetaxel.</TD><TD valign="top">No data. Docetaxel dose may need to be increased.</TD>
</TR>
<TR>
<TD valign="top"><B>Echinacea</B></TD><TD valign="top">May decrease EFV serum level. Echinacea decreased CYP3A4 substrate (midazolam) by 23%.</TD><TD valign="top">Clinical significance unknown but should avoided until the safety of this combination is further evaluated.</TD>
</TR>
<TR>
<TD valign="top"><B>Ergot derivatives</B></TD><TD valign="top">May significantly increase serum level of ergotamine resulting in acute ergot toxicity.</TD><TD valign="top">Contraindicated. Consider alternative agent for migraine such as sumatriptan but not eletriptan, since it is a CYP3A4 substrate and significant drug-drug interaction occurred with CYP3A4 inhibitor.</TD>
</TR>
<TR>
<TD valign="top"><B>Ethinyl Estradiol</B></TD><TD valign="top">Ethinyl estradiol AUC increased 37%.</TD><TD valign="top">Clinical significance unknown. No data on progesterone component of oral contraceptive available. Alternative form of birth control should be recommended.</TD>
</TR>
<TR>
<TD valign="top"><B>Etoposide</B></TD><TD valign="top">May decrease serum level of etoposide.</TD><TD valign="top">No data. Etoposide dose may need to be increased.</TD>
</TR>
<TR>
<TD valign="top"><B>Famotidine</B></TD><TD valign="top">No significant interaction.</TD><TD valign="top">Use standard dose.</TD>
</TR>
<TR>
<TD valign="top"><B>Fatty meal (54% fat) or low fat meal (4%)</B></TD><TD valign="top">EFV AUC increased by 50% and 22% with high fat and low fat meal, respectively. Fatty meal increased EFV tabs Cmax by 79% and EFV caps Cmax by 51%. </TD><TD valign="top">Manufacturer recommends taking EFV on an empty stomach due to the potential for increased CNS side effect from high EFV Cmax. May not be necessary after initial side effects have resolved.</TD>
</TR>
<TR>
<TD valign="top"><B>Fluoxetine</B></TD><TD valign="top">EFV AUC not significantly affected by SSRI (population PK).</TD><TD valign="top">No significant interaction. Use standard dose.</TD>
</TR>
<TR>
<TD valign="top"><B>Garlic supplement </B></TD><TD valign="top">No data.</TD><TD valign="top">Reduction on <A class="headLines" target="_new" href="saquinavir964d.html?contentInstanceId=432951">SQV</A> serum level. No data with EFV. Avoid co-administration.</TD>
</TR>
<TR>
<TD valign="top"><B>Heroin (Diamorphine)</B></TD><TD valign="top">Drug interactions unlikely.</TD><TD valign="top">Interaction unlikely but illicit drug use should be avoided for obvious reasons.</TD>
</TR>
<TR>
<TD valign="top"><B>Ifosphamide</B></TD><TD valign="top">May decrease serum level of ifosphamide.</TD><TD valign="top">Applies to EFV and <A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">NVP</A>: No data. Ifosphamide dose may need to be increased.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Itraconazole
          </B></TD><TD valign="top">Itraconazole AUC decreased by 39%. EFV AUC not affected. </TD><TD valign="top">For invasive fungal infections, monitor itraconazole serum levels with co-administration. Consider alternative antifungal (i.e. <A class="headLines" target="_new" href="../antimicrobial_agents/fluconazoled462.html?contentInstanceId=434183">fluconazole</A>: no significant interaction).</TD>
</TR>
<TR>
<TD valign="top"><B>
            Ketoconazole
          </B></TD><TD valign="top">May decrease ketoconazole serum levels.</TD><TD valign="top">May need to increase ketoconazole dose (i.e. <A class="headLines" target="_new" href="../antimicrobial_agents/fluconazoled462.html?contentInstanceId=434183">fluconazole</A>: no significant interaction).</TD>
</TR>
<TR>
<TD valign="top"><B>
            Lorazepam
          </B></TD><TD valign="top">No significant change.</TD><TD valign="top">Use standard dose.</TD>
</TR>
<TR>
<TD valign="top"><B>&nbsp;Maraviroc</B></TD><TD valign="top">Maraviroc AUC decreased by 45%. </TD><TD valign="top">Maraviroc 600 mg BID + EFV 600 mg qhs. If PIs (i.e <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV/r</A>&nbsp;or SQV/r) are&nbsp;included in regimen, standard dose MVC recommended.</TD>
</TR>
<TR>
<TD valign="top"><B>Medroxyprogesterone (DMPA) </B></TD><TD valign="top">No significant drug interaction. EFV AUC was not significantly affected.&nbsp;DMPA concentrations were not reported.</TD><TD valign="top">Efficacy of DMPA was not affected by EFV co-administration. Use standard dose of both drugs. Counsel patient on the potential for teratogenicity of EFV. </TD>
</TR>
<TR>
<TD valign="top"><B>
            Mefloquine
          </B></TD><TD valign="top">May decrease serum level of mefloquine.</TD><TD valign="top">If available consider mefloquine serum level monitoring. Close monitoring of mefloquine therapeutic efficacy (i.e. parasite count on blood smear and clinical signs and sx of clinical improvement).</TD>
</TR>
<TR>
<TD valign="top"><B>
            Methadone
          </B></TD><TD valign="top">Methadone AUC: decreased 57%.</TD><TD valign="top">Monitor for opiate withdrawal. May need to increase the maintenance dose of methadone.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Midazolam
          </B></TD><TD valign="top">May increase midazolam level.</TD><TD valign="top">Do not co-administer. Consider lorazepam (not significantly affected by EFV), oxazepam, or temazepam.</TD>
</TR>
<TR>
<TD valign="top"><B>Milk thistle </B></TD><TD valign="top">No data.</TD><TD valign="top">Data limited to interaction study with milk thistle and <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A>. <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A> AUC unchanged; <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A> Cmin decreased by 47%. Clinical significance unknown. Avoid co-administration. </TD>
</TR>
<TR>
<TD valign="top"><B>Mycophenolate</B></TD><TD valign="top">Interaction unlikely. No significant interaction observed with <A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">NVP</A>.</TD><TD valign="top">No significant interaction observed with <A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">NVP</A>. Use standard dose.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Paclitaxel
          </B></TD><TD valign="top">May decrease serum level of paclitaxel.</TD><TD valign="top">Applies to EFV and <A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">NVP</A>: No data. Monitor for chemotherapeutic response. Paclitaxel dose may need to be increased.</TD>
</TR>
<TR>
<TD valign="top"><B>Paroxetine</B></TD><TD valign="top">Paroxetine AUC not affected.</TD><TD valign="top">No significant interaction. Use standard dose.</TD>
</TR>
<TR>
<TD valign="top"><B>Phenobarbital</B></TD><TD valign="top">EFV and anticonvulsants levels may be decreased.</TD><TD valign="top">Consider alternative anticonvulsants (i.e. valproic acid, lamotrigine, levetiracetam, or topiramate). With co-administration, monitor anticonvulsants level and consider EFV TDM.</TD>
</TR>
<TR>
<TD valign="top"><B>Phenytoin</B></TD><TD valign="top">EFV and anticonvulsants levels may be decreased.</TD><TD valign="top">Consider alternative anticonvulsants (i.e. valproic acid, lamotrigine, levetiracetam, or topiramate). With co-administration, monitor anticonvulsants level and consider EFV TDM.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Pravastatin
          </B></TD><TD valign="top">Pravastatin AUC decreased 44%.</TD><TD valign="top">Clinical significance unknown. May need to increase dose of pravastatin.</TD>
</TR>
<TR>
<TD valign="top"><B>Raltegravir (MK-0518) </B></TD><TD valign="top">Raltegravir AUC decreased by 36%. </TD><TD valign="top">Dose not established. </TD>
</TR>
<TR>
<TD valign="top"><B>
            Rifabutin
          </B></TD><TD valign="top">Rifabutin AUC: decreased 38% No change in EFV AUC.</TD><TD valign="top">Recommended dosing: Increase rifabutin to 450 mg/d or 600 mg 3x/wk with EFV 600 mg qhs.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Rifapentine
          </B></TD><TD valign="top">EFV serum levels may be significantly decreased.</TD><TD valign="top">Avoid co-administration. Consider using rifabutin with dose adjustment.</TD>
</TR>
<TR>
<TD valign="top"><B>Rosiglitazone</B></TD><TD valign="top">EFV Cmin decreased by 6% (non-significant) (n=10).</TD><TD valign="top">Use standard dose.</TD>
</TR>
<TR>
<TD valign="top"><B>Rosuvastatin&nbsp;&nbsp;</B></TD><TD valign="top">Other CYP3A4 inhibitor (i.e <A class="headLines" target="_new" href="../antimicrobial_agents/erythromycin329b.html?contentInstanceId=434157">erythromycin</A>) did not affect rosuvastatin serum level.</TD><TD valign="top">Rosuvastatin AUC and Cmax unexpectedly increased 2.1 and 4.7-fold at steady state with <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV/r</A> co-administration. Despite increased rosuvastatin exposure, the LDL-lowering effects were attenuated with <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV/r</A> co-administration. Close monitoring recommended due to limited clinical data.</TD>
</TR>
<TR>
<TD valign="top"><B>Sertraline</B></TD><TD valign="top">Sertraline AUC decreased 39%.</TD><TD valign="top">Titrate sertraline to effect.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Simvastatin
          </B></TD><TD valign="top">Simvastatin: AUC decreased by 68%.</TD><TD valign="top">May require simvastatin dose increase with close monitoring of LFTs and CPK.</TD>
</TR>
<TR>
<TD valign="top"><B>Sirolimus</B></TD><TD valign="top">May significantly decrease serum level of sirolimus.</TD><TD valign="top">Applies to EFV and <A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">NVP</A>: dose sirolimus based on serum level. May need to increase sirolimus dose.</TD>
</TR>
<TR>
<TD valign="top"><B>St. John's wort</B></TD><TD valign="top">Not studied, may decrease EFV levels.</TD><TD valign="top">Contraindicated. Use an alternative (more effective) antidepressant.</TD>
</TR>
<TR>
<TD valign="top"><B>Tacrolimus</B></TD><TD valign="top">May significantly decrease serum level of tacrolimus.</TD><TD valign="top">Dose tacrolimus based on serum level. May need to increase tacrolimus dose.</TD>
</TR>
<TR>
<TD valign="top"><B>Tamoxifen</B></TD><TD valign="top">May decrease serum level of tamoxifen.</TD><TD valign="top">No data. Monitor for chemotherapeutic response. Tamoxifen dose may need to be increased.</TD>
</TR>
<TR>
<TD valign="top"><B>Teniposide</B></TD><TD valign="top">May decrease serum level of teniposide.</TD><TD valign="top">No data. Monitor for chemotherapeutic response. Teniposide dose may need to be increased.</TD>
</TR>
<TR>
<TD valign="top"><B>Terfenadine</B></TD><TD valign="top">May significantly increase terfenadine serum level.</TD><TD valign="top">Contraindicated due to the potential for cardiac arrhythmias. Recommended alternative antihistamine: loratadine, fexofenadine, desloratidine, or cetirizine.</TD>
</TR>
<TR>
<TD valign="top"><B>THC</B></TD><TD valign="top">Based on data with <A class="headLines" target="_new" href="nelfinaviraafb.html?contentInstanceId=432948">NFV</A> and <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A> interactions are unlikely.</TD><TD valign="top">Applies to PIs and NNRTIs: Interactions are unlikely but illicit drug use should be avoided for obvious reasons.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Triazolam
          </B></TD><TD valign="top">May increase triazolam serum level.</TD><TD valign="top">Contraindicated. Consider lorazepam (not significantly affected by EFV), oxazepam, or temazepam.</TD>
</TR>
<TR>
<TD valign="top"><B>Vinblastine</B></TD><TD valign="top">May decrease serum level of vinblastine.</TD><TD valign="top">Applies to EFV and <A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">NVP</A>: No data. Monitor for chemotherapeutic response. Vinblastine dose may need to be increased.</TD>
</TR>
<TR>
<TD valign="top"><B>Vincristine</B></TD><TD valign="top">May decrease serum level of vincristine.</TD><TD valign="top">Applies to EFV and <A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">NVP</A>: No data. Monitor for chemotherapeutic response. Vincristine dose may need to be increased.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Voriconazole
          </B></TD><TD valign="top">EFV (400 mg PO qd) decreased steady state voriconazole (200 mg q12h) AUC by 77%. EFV AUC was increased by 44%. No significant change in voriconazole and EFV AUC with voriconazole 400 mg q12h plus EFV 300 mg qhs.</TD><TD valign="top">EFV should not be co-administered with voriconazole&nbsp;at the standard doses. . </TD>
</TR>
<TR>
<TD valign="top"><B>Warfarin</B></TD><TD valign="top">Not studied; may increase or decrease warfarin effects;&nbsp;monitor INR and adjust warfarin as indicated.</TD><TD valign="top">Monitor INR and adjust warfarin as indicated.</TD>
</TR>
</TABLE>
<a name="RESISTANCE"></a>
<h2 class="grayLineHeaderBar">RESISTANCE</h2>
<ul>
<li>K103N: Most common mutation selected by EFV, resulting in high-level resistance to EFV, <A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">NVP</A>, <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>.</li>
<li>Y181 mutations: 181C/I: resistance to <A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">NPV</A>, <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>, low-level resistance to EFV (minimal clinical data on use of EFV with 181C/I). 181C can partially reverse TAM-mediated <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A>, <A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF</A> resistance to V108I </li>
<li>Y188 mutations: 188L high-level resistance to <A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">NVP</A>, EFV, intermediate resistance to <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>; 188C: high-level resistance to <A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">NVP</A>, low-level resistance to EFV, <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>; 188H: low-level resistance to <A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">NVP</A>, EFV, DLV. </li>
<li>G190 mutations: 190A: high-level resistance to <A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">NVP</A>, intermediate resistance to EFV; 190S: high-level resistance to NPV, EFV; both cause hypersusceptibility to <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A> (unknown clinical significance). </li>
<li>L100I: intermediate resistance to EFV, <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>; low-level resistance to <A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">NVP</A>; can partially reverse TAM-mediated <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A>, <A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF</A> resistance. </li>
<li>V106 mutations: 106A: low-level EFV resistance, high-level <A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">NPV</A> resistance, intermediate <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A> resistance; 106M: high-level resistance to EFV, NPV, intermediate resistance to DLV; 106I: not associated with resistance .</li>
<li>P225H: increases EFV resistance when combined with other NNRTI mutations.</li>
<li>V108I: low-level resistance to EFV and other NNRTIs. Clinically insignificant when present as sole mutation. </li>
</ul>
<a name="PHARMACOLOGY"></a>
<h2 class="grayLineHeaderBar">PHARMACOLOGY</h2>
<a name="N10EC3"></a>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">MECHANISM</span></td>
</tr>
</table>
<hr>Non-competitive inhibition of HIV DNA polymerase resulting in disruption of catalytic site of the enzyme.<br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">PHARMACOKINETIC PARAMETERS</span></td>
</tr>
</table>
<hr>
<ul>
<li>Absorption: 
                40-45% absorption with or without food; high fat meals increase absorption by 39% (caps) to 79% (tabs)</li>
<li>Metabolism and Excretion: 
                Metabolized by CYP3A4 and CYP2D6 to several hydroxylated metabolites, which undergo subsequent glucuronidation. Both unchanged drug and metabolites are excreted in the feces.</li>
<li>Protein Binding: 
                99.5-99.75%</li>
<li>Cmax, Cmin, and AUC: 
                Steady-state (600 mg) mean Cmax="13" micromole per mL; Cmin = "5.6" micromole/mL; AUC = "184" micromole/mL hr.</li>
<li>T1/2: 
                36-100 hrs. Recent study found that the 516T/T genotype (more frequently found in African Americans) was associated with higher plasma EFV concentrations, slower clearance, and increased CNS toxicity.</li>
</ul>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING FOR DECREASED HEPATIC FUNCTION</span></td>
</tr>
</table>
<hr>600 mg qhs (serum level may be increased with ESLD).<br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">PREGNANCY RISK</span></td>
</tr>
</table>
<hr>Category D: Placental passage of 100% seen in cynomolgus monkeys, rats and rabbits. Teratogenicity demonstrated in cynomolgus monkeys resulting in anencephaly. Five cases of neural tube defects reported. Women with childbearing potential should be counseled about adequate contraceptive protection.<br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">BREAST FEEDING COMPATIBILITY</span></td>
</tr>
</table>
<hr>No human data, breast milk excretion in animal studies. Breast feeding is not recommended in the U.S. in order to avoid post-natal transmission of HIV to the child, who may not yet be infected.<a name="COMMENTS"></a>
<h2 class="grayLineHeaderBar">COMMENTS</h2>
<ul>
<li>Pros: Multiple studies demonstrating potency and durability, including in pts with high VL and/or low CD4; convenient (1 pill qd), including co-formulation with <A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF</A> and <A class="headLines" target="_new" href="emtricitabine63e5.html?contentInstanceId=432943">FTC</A> (<I>Atripla</I>); generally well tolerated; minimal long-term toxicity; less <A class="headLines" target="_new" href="../../diagnosis/complications_of_therapy/hepatotoxicity0e98.html?contentInstanceId=434823">hepatotoxicity</A> and less severe rash than with <A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">NVP</A>; long half-life (forgiving of delayed or missed doses); a preferred agent in DHHS guidelines with more rapid 1st phase virologic decay and superior virologic efficacy compared to <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV/r</A> containing regimen in ACTG 5142;</li>
<li>Cons: Early CNS side effects common and require pt education/counseling; more <A class="headLines" target="_new" href="../../diagnosis/complications_of_therapy/hyperlipidemia4edb.html?contentInstanceId=434827">hyperlipidemia</A> than with <A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">NVP</A> (though less than with most PIs); low genetic barrier (single point mutation) to resistance; long-half life may increase risk of resistance in pts who interrupt therapy. Lower CD4 increase and more <A class="headLines" target="_new" href="../../diagnosis/complications_of_therapy/lipodystrophy94a9.html?contentInstanceId=432804">lipoatrophy</A> than with <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV/r</A> in ACTG 5142. (<A class="headLines" target="_new" href="../../diagnosis/complications_of_therapy/lipodystrophy94a9.html?contentInstanceId=432804">Lipoatrophy</A> difference probably applies only to <A class="headLines" target="_new" href="stavudinec8c7.html?contentInstanceId=432952">d4T</A>- or <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A>-containing regimens.)</li>
</ul>
<a name="N10F37"></a><a name="References"></a>
<h2 class="grayLineHeaderBar">References</h2>
<ol>
<li>Bartlett JA, Johnson J, Herrera G, et al.;
		Long-term results of initial therapy with abacavir and Lamivudine combined with Efavirenz, Amprenavir/Ritonavir, or Stavudine.;        
		J Acquir Immune Defic Syndr;
		2006; Vol. 
		43; pp. 
		284-92;
		<br>ISSN:
	        	1525-4135;
	        <br>PUBMED: <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=16967040&amp;dopt=abstract" target="_new">16967040</a>
<br>
<b>Comments:</b>291 naive pts with med. baseline VL 63,000-79,000 and CD4 296-307 received <A class="headLines" target="_new" href="abacavirc37e.html?contentInstanceId=432939">ABC</A>/<A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A> 300/150 mg bid combined with either an NNRTI qd, PI qd, or NRTI bid. Pts in EFV arm had longer duration of VL suppression compared to the NRTI arm (VL &lt;400, p=0.007). However, at wk 96, there were no differences between arms in the % of subjects with VL &lt;400 and &lt;50. Med. CD4 increase and incidence of AEs were similar between arms. <br>
<br>
</li>
<li>Gallant JE, DeJesus E, Arribas JR, et al.;
		Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.;        
		N Engl J Med;
		2006; Vol. 
		354; pp. 
		251-60;
		<br>ISSN:
	        	1533-4406;
	        <br>PUBMED: <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=16421366&amp;dopt=abstract" target="_new">16421366</a>
<br>
<b>Comments:</b>Ongoing 144-wk multicenter, open-label trial comparing <A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF</A> + <A class="headLines" target="_new" href="emtricitabine63e5.html?contentInstanceId=432943">FTC</A> vs. co-formulated <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A>/<A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A>, both administered in combination with EFV, in 509 treatment-nave pts. Mean baseline VL 5.0 log10 . At 48 wks, 84% of the 487 evaluable pts in the <A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF</A> + <A class="headLines" target="_new" href="emtricitabine63e5.html?contentInstanceId=432943">FTC</A> arm had a Vl &lt;400 compared to 73% in the <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A>/<A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A> arm (p=0.002) by the FDA-mandated time to loss of viral response analysis. Suppression to &lt;50 achieved in 80 and 70% of pts, respectively (p=0.02). Higher ITT success rate in the <A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF</A>/<A class="headLines" target="_new" href="emtricitabine63e5.html?contentInstanceId=432943">FTC</A> arm was due to a higher rate of discontinuation caused by adverse events in the <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A>/<A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A> arm (9% vs 4%; p=0.016), with 6% discontinuing due to <A class="headLines" target="_new" href="../../diagnosis/organ_system/anemiac7e4.html?contentInstanceId=432360">anemia</A>. Limb fat at week 96 was significantly greater in the <A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF</A> + <A class="headLines" target="_new" href="emtricitabine63e5.html?contentInstanceId=432943">FTC</A> + EFV group versus the ZDV/<A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A> + EFV group (7.7 vs. 5.5 kg; P &lt; 0.001) (<A class="headLines" target="_new" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=17057609&amp;dopt=abstract">J Acquir Immune Defic Syndr. 2006;43(5):535-40</A>.)<br>
<br>
</li>
<li>Gulick RM, Ribaudo HJ, Shikuma CM, et al.;
		Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial.;        
		JAMA;
		2006; Vol. 
		296; pp. 
		769-81;
		<br>ISSN:
	        	1538-3598;
	        <br>PUBMED: <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=16905783&amp;dopt=abstract" target="_new">16905783</a>
<br>
<b>Comments:</b>The continuation of ACTG 5095 compared <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A>/<A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A>/EFV to <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A>/<A class="headLines" target="_new" href="abacavirc37e.html?contentInstanceId=432939">ABC</A>/<A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A>/EFV in ART-naive pts. No significant differences between 3vs 4-drug regimens; approximately 80% of pts had VL &lt; 50 through 3 yrs. 10% treated with <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A>/<A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A>/<A class="headLines" target="_new" href="abacavirc37e.html?contentInstanceId=432939">ABC</A>/EFV had <A class="headLines" target="_new" href="abacavirc37e.html?contentInstanceId=432939">ABC</A> HSR, vs. 7% on <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A>/<A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A>/EFV. <br>
<br>
</li>
<li>Riddler SA, Haubrich R, DiRienzo G, et al. ;
		A prospective, randomized, phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection: ACTG 5142. ;        
		Program and abstracts of the XVI International AIDS Conference; August 13-18, 2006; Toronto, Canada. Abstract THLB0204. ;
		2006; Vol. 
		<br>
<b>Comments:</b>753 ARV-naive pts randomized to 3 regimens: LPV/rtv + NRTIs, EFV + NRTIs, and lpv/rtv + EFV. At 96 wks, 89% of pts in the EFV + 2NRTIs arm had a VL &lt;50 compared to 77% in the <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV/r</A> + 2 NRTIs arm (p=0.003). <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV/r</A> + EFV arm had similar virologic efficacy compared to EFV + 2 NRTIs. There was no difference between the 3 arms in time to first treatment-limiting toxicity. Phase 1 viral decay half-life was significantly shorter for EFV than <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV/r</A> (1.1 vs 1.3 days, p = 0.03). Despite superior virologic response in the EFV+2 NRTIs regimen, <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV/r</A> containing regimen resulted in higher increases in CD4 response (241 vs. 285, p=0.01) and less lipoatrophy. In pts with virologic failure, development of resistance was more common in the NNRTI + 2 NRTIs arm than either <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV/r</A>- containing arm. <br>
<br>
</li>
<li>van Leth F, Phanuphak P, Ruxrungtham K, et al.;
		Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study.;        
		Lancet;
		2004; Vol. 
		363; pp. 
		1253-63;
		<br>ISSN:
	        	1474-547X;
	        <br>PUBMED: <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=15094269&amp;dopt=abstract" target="_new">15094269</a>
<br>
<b>Comments:</b>Large, prospective, randomized trial comparing <A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">NVP</A> 400 mg qd, <A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">NVP</A> 200 mg bid, EFV 600 mg qd, or <A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">NVP</A> 400 mg + EFV 800 mg qd, + <A class="headLines" target="_new" href="stavudinec8c7.html?contentInstanceId=432952">d4T</A> and <A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A>, for 48 wks in 1216 naive pts. EFV and <A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">NVP</A> regimens comparable, with VL &lt;50 in 65% vs 60%, respectively at 48 wks (p=0.193), but did not meet study criteria for non-inferiority (within the 10% limit). <A class="headLines" target="_new" href="../../diagnosis/complications_of_therapy/hepatotoxicity0e98.html?contentInstanceId=434823">Hepatotoxicity</A> more common in <A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">NVP</A> arm (9.6 vs 3.5%).<br>
<br>
</li>
<li>Squires K, Lazzarin A, Gatell JM, et al.;
		Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV.;        
		J Acquir Immune Defic Syndr;
		2004; Vol. 
		36; pp. 
		1011-9;
		<br>ISSN:
	        	1525-4135;
	        <br>PUBMED: <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=15247553&amp;dopt=abstract" target="_new">15247553</a>
<br>
<b>Comments:</b>Randomized, double-blind study involving 810 naive pts compared <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A> 400 mg qd to EFV 600 mg qhs in combination with open-label fixed-dose <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A>/<A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A> bid. At week 48, VL &lt;400 in 70% of pts receiving <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A> and 64% of pts receiving EFV (NS). Unboosted <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A> was equivalent to EFV in ART naive pts.<br>
<br>
</li>
<li>Gallant JE, Staszewski S, Pozniak AL, et al.;
		Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.;        
		JAMA;
		2004; Vol. 
		292; pp. 
		191-201;
		<br>ISSN:
	        	1538-3598;
	        <br>PUBMED: <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=15249568&amp;dopt=abstract" target="_new">15249568</a>
<br>
<b>Comments:</b>602 ART naive pts randomized to receive either <A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF</A> (n = 299) or <A class="headLines" target="_new" href="stavudinec8c7.html?contentInstanceId=432952">d4T</A> (n = 303), with placebo, in combination with <A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A> and EFV. The proportion of pts with VL &lt;400 at week 48 was 239/299 (80%) and 253/301 (84%) in pts receiving <A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">TDF</A> and <A class="headLines" target="_new" href="stavudinec8c7.html?contentInstanceId=432952">d4T</A>, respectively. Virologic results equivalent but more <A class="headLines" target="_new" href="../../diagnosis/complications_of_therapy/lipodystrophy94a9.html?contentInstanceId=432804">lipoatrophy</A>, neuropathy and <A class="headLines" target="_new" href="../../diagnosis/complications_of_therapy/hyperlipidemia4edb.html?contentInstanceId=434827">hyperlipidemia</A> in <A class="headLines" target="_new" href="stavudinec8c7.html?contentInstanceId=432952">d4T</A> arm.<br>
<br>
</li>
<li>Gulick RM, Ribaudo HJ, Shikuma CM, et al.;
		Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.;        
		N Engl J Med;
		2004; Vol. 
		350; pp. 
		1850-61;
		<br>ISSN:
	        	1533-4406;
	        <br>PUBMED: <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=15115831&amp;dopt=abstract" target="_new">15115831</a>
<br>
<b>Comments:</b>Randomized, double-blind study comparing 3 regimens (<A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A>/<A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A>/<A class="headLines" target="_new" href="abacavirc37e.html?contentInstanceId=432939">ABC</A>, <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A>/<A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A> + EFV, <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A>/<A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A>/<A class="headLines" target="_new" href="abacavirc37e.html?contentInstanceId=432939">ABC</A> + EFV) as initial treatment in ART-naive pts. After med. follow-up of 32 wks, 82/ 382 subjects in triple-NRTI arm (21%) and 85/ 765 in combined EFV groups (11%) had virologic failure; time to virologic failure significantly shorter in the triple-NRTI arm (p &lt;0.001). <br>
<br>
</li>
<li>Haas D, Ribaudo H, Kim R, et al. ;
		A common CYP2B6 Variant is Associated with Efavirenz Pharmacokinetics and Central Nervous System Side Effects: AACTG Study NWCS214 ;        
		11th CROI, San Francisco, California, 2004. Abstract 133. ;
		2004; Vol. 
		<br>
<b>Comments:</b>516T/T genotype (more frequently found in African Americans) was associated with higher plasma EFV concentrations, slower clearance, and increased CNS toxicity. <br>
<br>
</li>
<li>Robbins GK, De Gruttola V, Shafer RW, et al.;
		Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection.;        
		N Engl J Med;
		2003; Vol. 
		349; pp. 
		2293-303;
		<br>ISSN:
	        	1533-4406;
	        <br>PUBMED: <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=14668455&amp;dopt=abstract" target="_new">14668455</a>
<br>
<b>Comments:</b>620 pts randomized to compare sequential 3-drug regimens in 3 groups: EFV-based HAART combined with <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A>/<A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A> or <A class="headLines" target="_new" href="stavudinec8c7.html?contentInstanceId=432952">d4T</A>/<A class="headLines" target="_new" href="didanosine10dd.html?contentInstanceId=432941">ddI</A> OR <A class="headLines" target="_new" href="nelfinaviraafb.html?contentInstanceId=432948">NFV</A> + <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A>/<A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A> or <A class="headLines" target="_new" href="stavudinec8c7.html?contentInstanceId=432952">d4T</A>/<A class="headLines" target="_new" href="didanosine10dd.html?contentInstanceId=432941">ddI</A>. EFV out performed <A class="headLines" target="_new" href="nelfinaviraafb.html?contentInstanceId=432948">NFV</A> in all arms. With a med. of 2-3 yr follow-up, virologic failure in 14% and 23% of EFV + <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A>/<A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A>-treated pts with the 1st and 2nd regimen, respectively. Higher rate of virologic failure in EFV + <A class="headLines" target="_new" href="stavudinec8c7.html?contentInstanceId=432952">d4T</A> + <A class="headLines" target="_new" href="didanosine10dd.html?contentInstanceId=432941">ddI</A> arm (31% and 58%). <br>
<br>
</li>
<li>Staszewski S, Morales-Ramirez J, Tashima KT, et al.;
		Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team.;        
		N Engl J Med;
		1999; Vol. 
		341; pp. 
		1865-73;
		<br>ISSN:
	        	0028-4793;
	        <br>PUBMED: <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=10601505&amp;dopt=abstract" target="_new">10601505</a>
<br>
<b>Comments:</b>Open-label study involving 450 pts naive to <A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A>, NNRTIs and PIs: randomized to receive EFV + <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A>/<A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A>; <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A> + <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A>/<A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A>; or EFV + <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A>. At 48 wks VL &lt;50 was achieved in more pts in EFV + <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A>/<A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A> group than in <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A> + <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A>/<A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A> group by ITT analysis (64% vs. 43%, p &lt;0.01). More pts discontinuing treatment because of ADRs in the <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A> arm compared to EFV arm (43% vs. 27%, p=0.005).<br>
<br>
</li>
</ol>
<a name="REFERENCED WITHIN THIS GUIDE"></a>
<h2 class="grayLineHeaderBar">REFERENCED WITHIN THIS GUIDE</h2>
<ul>
<li>
<A class="headLines" target="_new" href="abacavir9b9a.html?contentInstanceId=432942&amp;siteId=429188">Abacavir</A>
</li>
<li>
<A class="headLines" target="_new" href="../../guidelines/zambia_hiv_national_guidelines/changing_or_stopping_art9b9a.html?contentInstanceId=432942&amp;siteId=429188">Changing or Stopping ART</A>
</li>
<li>
<A class="headLines" target="_new" href="../../diagnosis/organ_system/depression9b9a.html?contentInstanceId=432942&amp;siteId=429188">Depression</A>
</li>
<li>
<A class="headLines" target="_new" href="emtricitabine9b9a.html?contentInstanceId=432942&amp;siteId=429188">Emtricitabine</A>
</li>
<li>
<A class="headLines" target="_new" href="indinavir9b9a.html?contentInstanceId=432942&amp;siteId=429188">Indinavir</A>
</li>
<li>
<A class="headLines" target="_new" href="../../guidelines/zambia_hiv_national_guidelines/initial_regimen_for_arv_therapy9b9a.html?contentInstanceId=432942&amp;siteId=429188">Initial Regimen for ARV Therapy</A>
</li>
<li>
<A class="headLines" target="_new" href="lamivudine9b9a.html?contentInstanceId=432942&amp;siteId=429188">Lamivudine</A>
</li>
<li>
<A class="headLines" target="_new" href="lopinavir_ritonavir9b9a.html?contentInstanceId=432942&amp;siteId=429188">Lopinavir/Ritonavir</A>
</li>
<li>
<A class="headLines" target="_new" href="nelfinavir9b9a.html?contentInstanceId=432942&amp;siteId=429188">Nelfinavir</A>
</li>
<li>
<A class="headLines" target="_new" href="nevirapine9b9a.html?contentInstanceId=432942&amp;siteId=429188">Nevirapine</A>
</li>
<li>
<A class="headLines" target="_new" href="../../guidelines/zambia_hiv_national_guidelines/nutrition_care_and_support9b9a.html?contentInstanceId=432942&amp;siteId=429188">Nutrition Care and Support</A>
</li>
<li>
<A class="headLines" target="_new" href="../../management/antiretroviral_therapy/pregnancy_and_perinatal_transmission__zambia_specific_9b9a.html?contentInstanceId=432942&amp;siteId=429188">Pregnancy and perinatal transmission (Zambia specific)</A>
</li>
<li>
<A class="headLines" target="_new" href="../antimicrobial_agents/rifampicin9b9a.html?contentInstanceId=432942&amp;siteId=429188">Rifampicin</A>
</li>
<li>
<A class="headLines" target="_new" href="../../guidelines/zambia_hiv_national_guidelines/stopping_arv_therapy9b9a.html?contentInstanceId=432942&amp;siteId=429188">Stopping ARV Therapy</A>
</li>
<li>
<A class="headLines" target="_new" href="tenofovir9b9a.html?contentInstanceId=432942&amp;siteId=429188">Tenofovir</A>
</li>
<li>
<A class="headLines" target="_new" href="../../diagnosis/organ_system/thrombocytopenia9b9a.html?contentInstanceId=432942&amp;siteId=429188">Thrombocytopenia</A>
</li>
<li>
<A class="headLines" target="_new" href="../../management/antiretroviral_therapy/toxicity___side_effects__switching_therapy__zambia_spec9b9a.html?contentInstanceId=432942&amp;siteId=429188">Toxicity &amp; side effects: switching therapy (Zambia specific)</A>
</li>
<li>
<A class="headLines" target="_new" href="../../management/antiretroviral_therapy/treatment_interruption9b9a.html?contentInstanceId=432942&amp;siteId=429188">Treatment interruption</A>
</li>
<li>
<A class="headLines" target="_new" href="../../pathogens/parasites/trichomonas_vaginalis9b9a.html?contentInstanceId=432942&amp;siteId=429188">Trichomonas vaginalis</A>
</li>
<li>
<A class="headLines" target="_new" href="../../diagnosis/opportunistic_infections/tuberculosis__active__zambia_specific_9b9a.html?contentInstanceId=432942&amp;siteId=429188">Tuberculosis, Active (Zambia specific)</A>
</li>
<li>
<A class="headLines" target="_new" href="zidovudine9b9a.html?contentInstanceId=432942&amp;siteId=429188">Zidovudine</A>
</li>
<li>
<A class="headLines" target="_new" href="../antimicrobial_agents/artemether_lumefantrine9b9a.html?contentInstanceId=432942&amp;siteId=429188">artemether/lumefantrine</A>
</li>
</ul>
<br>
</td>
</tr>
</table>
</td><td></td>
</tr>
</table>
<p></p>
<table cellpadding="0" cellspacing="0" border="0" >
<tr>
<td bgcolor="#003366"></td><td class="bottomNav" bgcolor="#003366" >
<center>
<span class="copyrightFullModule">Copyright 2000-2008 Johns Hopkins University.  All rights reserved.</span>
</center>
</td>
</tr>
</table>
</body>

<!-- Mirrored from www.zambiahivguide.org/drugs/antiretrovirals/full_efavirenz.html by HTTrack Website Copier/3.x [XR&CO'2007], Thu, 19 Jun 2008 21:22:26 GMT -->
</html>
